Indication: Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)

Locally Advanced, Unresectable, Stage III

Sub-indication: Unresectable, Stage III NSCLC who have not progressed after cCRT.

Line of Therapy: Locally Advanced/Adjuvant

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: MedImmune, LLC, subsidiary of AstraZeneca PLC

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.